Royal Bank Of Canada Raises Revolution Medicines (NASDAQ:RVMD) Price Target to $165.00

Revolution Medicines (NASDAQ:RVMD) had its price objective raised by analysts at Royal Bank Of Canada to $165.00 in a note issued to investors on Thursday,Benzinga reports. The firm presently has an “outperform” rating on the stock. Royal Bank Of Canada’s target price would suggest a potential upside of 16.35% from the company’s previous close.

Several other research firms also recently issued reports on RVMD. Benchmark reaffirmed an “overweight” rating on shares of Revolution Medicines in a research note on Tuesday, February 17th. Piper Sandler upped their price objective on Revolution Medicines to $172.00 and gave the company an “overweight” rating in a research note on Thursday. HC Wainwright reaffirmed a “buy” rating on shares of Revolution Medicines in a research note on Wednesday, April 22nd. Stifel Nicolaus reaffirmed a “buy” rating on shares of Revolution Medicines in a research note on Monday, April 20th. Finally, Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Revolution Medicines in a research note on Tuesday, April 21st. Four analysts have rated the stock with a Strong Buy rating, fifteen have assigned a Buy rating and one has given a Sell rating to the company. Based on data from MarketBeat, Revolution Medicines presently has a consensus rating of “Buy” and an average target price of $103.88.

Revolution Medicines Stock Performance

Revolution Medicines stock opened at $141.81 on Thursday. The business has a 50 day moving average of $113.41 and a 200-day moving average of $94.43. Revolution Medicines has a 1 year low of $34.00 and a 1 year high of $155.70. The company has a debt-to-equity ratio of 0.16, a current ratio of 7.14 and a quick ratio of 7.14. The company has a market capitalization of $30.15 billion, a P/E ratio of -20.06 and a beta of 1.41.

Revolution Medicines (NASDAQ:RVMD) last released its quarterly earnings data on Wednesday, May 6th. The company reported ($2.29) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.83) by ($0.46). During the same quarter in the prior year, the business earned ($1.13) earnings per share. On average, equities research analysts predict that Revolution Medicines will post -7.42 earnings per share for the current year.

Insider Activity

In other Revolution Medicines news, COO Margaret A. Horn sold 4,583 shares of the firm’s stock in a transaction that occurred on Tuesday, March 17th. The shares were sold at an average price of $99.48, for a total transaction of $455,916.84. Following the completion of the transaction, the chief operating officer owned 157,570 shares in the company, valued at approximately $15,675,063.60. This trade represents a 2.83% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, insider Mark A. Goldsmith sold 120,000 shares of the firm’s stock in a transaction that occurred on Wednesday, April 15th. The stock was sold at an average price of $150.09, for a total transaction of $18,010,800.00. Following the transaction, the insider owned 276,698 shares of the company’s stock, valued at approximately $41,529,602.82. The trade was a 30.25% decrease in their position. The SEC filing for this sale provides additional information. In the last quarter, insiders have sold 184,592 shares of company stock worth $24,499,532. 8.20% of the stock is owned by insiders.

Institutional Inflows and Outflows

Several hedge funds have recently added to or reduced their stakes in the company. Nextech Invest Ltd. grew its position in shares of Revolution Medicines by 20.7% during the 4th quarter. Nextech Invest Ltd. now owns 7,601,087 shares of the company’s stock worth $332,472,000 after buying an additional 1,304,347 shares during the period. Millennium Management LLC grew its position in shares of Revolution Medicines by 681.8% during the 1st quarter. Millennium Management LLC now owns 156,353 shares of the company’s stock worth $5,529,000 after buying an additional 136,353 shares during the period. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC grew its position in shares of Revolution Medicines by 14.2% during the 1st quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 300,196 shares of the company’s stock worth $10,615,000 after buying an additional 37,345 shares during the period. Invesco Ltd. grew its position in shares of Revolution Medicines by 19.3% during the 2nd quarter. Invesco Ltd. now owns 227,019 shares of the company’s stock worth $8,352,000 after buying an additional 36,760 shares during the period. Finally, Jump Financial LLC grew its position in shares of Revolution Medicines by 87.9% during the 2nd quarter. Jump Financial LLC now owns 15,258 shares of the company’s stock worth $561,000 after buying an additional 7,137 shares during the period. Institutional investors own 94.34% of the company’s stock.

Revolution Medicines News Roundup

Here are the key news stories impacting Revolution Medicines this week:

• Positive Sentiment: Piper Sandler raised its price target on Revolution Medicines to $172 and reiterated an overweight view, adding to recent bullish calls from other firms and reinforcing confidence in the company’s growth outlook. Revolution Medicines (NASDAQ:RVMD) Price Target Raised to $172.00 at Piper Sandler
• Positive Sentiment: Revolution Medicines announced publication of Phase 1/2 daraxonrasib data in the New England Journal of Medicine, strengthening the scientific case for its pivotal RASolute 302 pancreatic cancer trial. Revolution Medicines Announces Publication in New England Journal of Medicine of Phase 1/2 Clinical Data on Daraxonrasib in Pancreatic Cancer
• Positive Sentiment: Reuters reported that the company’s experimental pancreatic cancer drug showed a strong survival benefit in trials, which could boost confidence in RVMD’s lead program and long-term pipeline value. Promising Revolution Medicines pancreatic cancer drug has high rate of mostly manageable side effects
• Neutral Sentiment: Q1 earnings showed a wider-than-expected loss and the company raised its 2026 expense outlook, underscoring that RVMD is still investing heavily in R&D and commercial preparation. RVMD Reports Wider-Than-Expected Loss in Q1, Raises ’26 Expense View
• Neutral Sentiment: TipRanks highlighted a new warrant-related risk ahead of the 2026 expiry, noting possible dilution concerns and the possibility that the warrants could expire worthless, which adds a layer of uncertainty for shareholders. Revolution Medicines Warrants: Balancing Dilution Risk and Potential Worthlessness Ahead of 2026 Expiry
• Negative Sentiment: Despite the clinical progress, higher losses and rising spending could weigh on sentiment if investors focus on the company’s need for continued funding before any product revenue arrives. Revolution Medicines, Inc. (RVMD) Q1 2026 Earnings Call Transcript

Revolution Medicines Company Profile

Revolution Medicines is a clinical-stage biopharmaceutical company focused on discovering and developing small molecule therapies to treat RAS-dependent cancers and other diseases driven by the RAS/MAPK pathway. The company’s research efforts target historically “undruggable” proteins, aiming to inhibit critical nodes in cell signaling that promote tumor growth and therapeutic resistance.

The lead pipeline includes RMC-4630, a SHP2 inhibitor; RMC-6291, a selective KRAS G12C inhibitor; and RMC-6236, a pan-RAS inhibitor designed to address multiple RAS mutations.